Valuation: Spero Therapeutics, Inc.

Market Cap 6.93Cr 6.16Cr 5.75Cr 5.24Cr 9.88Cr 666.19Cr 9.97Cr 70Cr 27Cr 340.57Cr 26Cr 25Cr 1.09TCr P/E 2026 *
-2.05x
P/E 2027 * -11.3x
Enterprise Value 6.93Cr 6.16Cr 5.75Cr 5.24Cr 9.88Cr 666.19Cr 9.97Cr 70Cr 27Cr 340.57Cr 26Cr 25Cr 1.09TCr EV / Sales 2026 *
269x
EV / Sales 2027 * -
Free-Float
77.39%
Yield 2026 *
-
Yield 2027 * -
1 day-5.56%
1 week-3.25%
Current month-1.65%
1 month-2.46%
3 months-45.91%
6 months-51.03%
Current year-48.93%
1 week 1.17
Extreme 1.17
1.31
1 month 1.1
Extreme 1.1
1.44
Current year 1.08
Extreme 1.08
3.08
1 year 1.08
Extreme 1.08
3.08
3 years 0.51
Extreme 0.5052
3.22
5 years 0.51
Extreme 0.5052
18.84
10 years 0.51
Extreme 0.5052
23.64
Manager TitleAgeSince
Chief Executive Officer 47 10/01/2025
Chief Tech/Sci/R&D Officer 69 27/07/2026
Chief Operating Officer 58 01/02/2023
Director TitleAgeSince
Chairman 69 01/01/2014
Director/Board Member 62 01/09/2015
Chairman 56 10/01/2025
Date Insider Type Main position Quantity % Market Cap. Importance
03/08/26 Free

Chief Technology Officer

4,86,986 0.8411%
04/05/26 Sell

Chief Executive Officer

-25,240 0.0436%
06/02/26 Sell

Chief Executive Officer

87,917 0.1560%
Change 5-day change 1-year change 3-year change Capi.($)
-5.56%-3.25%-41.38%0.00% 6.93Cr
+4.16%+3.04%+49.37%+94.17% 7.42TCr
-3.11%-3.53%+21.92%+74.60% 5.74TCr
+0.89%-0.63%+4.28%+34.51% 4.76TCr
+0.36%+0.81%+352.17%+689.61% 4.43TCr
-0.96%-4.50%+26.36%+33.18% 4.25TCr
-0.20%-0.77%+3.74%+100.60% 4.07TCr
-0.54%+2.93%+9.31%+50.41% 3.1TCr
-2.68%+2.92%+29.63%+19.50% 2.85TCr
+0.05%-1.64%-7.28%-14.06% 2.43TCr
Average -0.76%-0.85%+44.81%+108.25% 3.91TCr
Weighted average by Cap. +0.12%-0.84%+58.75%+129.89%

Financials

2026 *2027 *
Net sales 3L 2L 2L 2L 4L 2.48Cr 4L 25.89L 10.03L 1.27Cr 10L 9L 4.07Cr -
Net income -3.35Cr -2.97Cr -2.77Cr -2.53Cr -4.77Cr -321.61Cr -4.81Cr -34Cr -13Cr -164.41Cr -13Cr -12Cr -527.66Cr -5.15Cr -4.58Cr -4.27Cr -3.89Cr -7.34Cr -495.08Cr -7.41Cr -52Cr -20Cr -253.09Cr -19Cr -19Cr -812.27Cr
Net Debt - -
Logo Spero Therapeutics, Inc.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Employees
25
Date Price Change Volume
02/26/02 $1.190 -5.56% 9,06,916
01/26/01 $1.260 +4.13% 10,39,210
30/26/30 $1.210 +0.83% 5,58,213
29/26/29 $1.200 +0.84% 3,34,908
28/26/28 $1.190 -3.25% 3,93,255
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.190USD
Average target price
5.000USD
Spread / Average Target
+320.17%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SPRO Stock